Accelerate to Discover

Back to filter

Related topics

Understanding the pathogenesis of FCD type II using qPCR

BJS Biotechnologies

Jul 18, 2018

The quantitative polymerase chain reaction is the methodology to determine the essential and dominant role of cNEUROG2...

B fibers are the best predictors of cardiac activity during Vagus nerve stimulation

VisualSonics FujiFilm

Jul 17, 2018

Vagus nerve stimulation (VNS) is a promising therapy for many neurologic and psychiatric conditions. However,...

New technologies to uncover the molecular basis of disorders of sex development

BioNano Genomics

Jul 13, 2018

Newer approaches, such as whole-genome sequencing and whole-genome mapping have the potential to identify novel...

δT cells and CD8+ T cells targeting of breast cancer cells

Etaluma

Jul 11, 2018

Cancer stem cells (CSCs) are a large cause of metastasis in breast cancer. They are also very resistent to any...

Jul 18, 2018

Incucyte system used for generating single-cell-derived cancer-associated fibroblast clones

Sartorius

Jul 9, 2018

Single-cell-derived cancer-associated fibroblast (CAFs) were produced using Incucyte. These cells were used to help...

Real-time study of platelet formation under sheer-flow with Lumascope

Etaluma

Jun 18, 2018

Platelet formation was observed with Lumascope microscope in a uniform-sheer-flow biorector. Videos of the formation...

Early fetal sex determination using micro-volume of maternal plasma

BJS Biotechnologies

Jun 16, 2018

 A qPCR-based assay, SneakPeek Early Gender Test (Gateway Genomics) has been developed to determine fetal sex as early...

Jul 18, 2018

3R Compliant drug development studies

Bruker Biospin

Jun 8, 2018

In preclinical imaging, magnetic resonance imaging (MRI) can be an attractive alternative to researchers who have...

Show all topics (10)

Homing in on directed imaging platforms

Aug 9, 2016

At the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Anna Wu, Ph.D., professor and chair of the department of molecular and medical pharmacology, has been engineering antibodies for both therapeutic and imaging purposes. Antibodies meant for imaging, she points out, reflect a slightly different set of engineering characteristics.

Dr. Wu works with colleagues at UCLA and ImaginAb (a company she co-founded in 2007 and now serves as chief scientist) to engineer labeled antibodies. Because Dr. Wu in interested in advancing positron emission tomography (PET) imaging, she is engineering antibodies that incorporate positron-emitting radionucleotides.

“Each imaging modality has its strengths and weaknesses,” notes Dr. Wu. “Magnetic resonance imaging (MRI) gives you anatomical and physiological imaging, but it doesn’t have the sensitivity of PET. PET has a higher resolution and sensitivity compared to single-photon emission computed tomography (SPECT), but it has lower resolution than MRI or CT.”

Dr. Wu has chosen PET because it fits well with her antibody fragments (called minibodies and diabodies) in a process coined immunoPET. She favors PET because it can, she says, be combined with the specificity of antibodies.

“One of the key features of antibodies is they have very long circulating half-lives,” she points out. “Antibodies stay in the blood for days to weeks.” To match the half-lives of antibodies, she and others have been testing longer-lived positron emitters, such as zirconium-89. “The fluorine-18 everyone uses has a two-hour half-life, so it’s a challenge to make a fragment that targets and clears quickly enough to image.” Zirconium-89, in contrast, has a half-life that is a little over three days.

Read more

Scientific paper

Related technologies: PET, SPECT, CT

Brand profile

Bruker Biospin

Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.

Related products

Albira combines PET, SPECT and CT imaging in a unique and extremely powerful way.

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey